FDA Inspection 1009013 — Stryker
The FDA completed an inspection of Stryker on Mar 20, 2017 in Phoenix, AZ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 20, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Human Cellular, Tissue, and Gene Therapies
- Location
- Phoenix, AZ (United States)